stockrow
Friday 6 November 2026
Export PODD’s income statement to Excel — free account
Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.
- Revenue
- +19.2%
- EPS
- +64.1%
- Free cash flow
- −29.8%
- Total debt
- −5.19%
Quarter to September 2026, against a year earlier
146.38
9.74
−6.24%
Follow PODD
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
21.23 | 28.46 | 48.80 | 81.21 |
+8 more quarters Free account |
P/S ratio |
2.84 | 3.46 | 5.06 | 7.38 | |
P/FCF ratio |
39.02 | 39.72 | 37.87 | 57.15 | |
P/Operating CF |
102.37 | 119.35 | 129.05 | 109.09 | |
P/B ratio |
6.36 | 7.42 | 11.27 | 13.20 | |
Price to Tangible BV |
7.21 | 8.40 | 12.93 | 14.85 | |
EV/Sales |
2.96 | 3.59 | 5.22 | 7.47 | |
EV/EBITDA |
13.60 | 17.83 | 25.17 | 35.85 | |
EV/Operating CF |
18.52 | 21.45 | 24.47 | 35.53 | |
EV/FCF |
40.65 | 41.28 | 39.08 | 57.81 | |
Quick Ratio |
1.56 | 1.51 | 1.49 | 1.81 | |
Current Ratio |
2.51 | 2.48 | 2.49 | 2.81 | |
Net Debt/EBITDA |
0.00 | 2.64 | 3.15 | 1.37 | |
Debt/Assets |
28.17% | 29.96% | 31.74% | 29.75% | |
Debt/Equity |
0.61 | 0.67 | 0.73 | 0.63 | |
Asset Turnover |
0.99 | 0.92 | 0.89 | 0.86 | |
Operating CF/Net income |
0.00 | 0.93 | 1.25 | 1.80 | |
Capex/Depreciation |
(2.02) | (1.40) | (1.06) | (6.12) | |
Interest Coverage |
15.69 | 9.61 | 8.31 | 9.75 | |
Research and Development Expense of Revenue |
10.88% | 10.99% | 11.78% | 11.60% | |
Selling, General and Administrative Expense of Revenue |
41.65% | 43.01% | 41.64% | 42.29% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.06 | 0.05 | |
Share Based Compensation of Revenue |
0.00% | 2.44% | 2.80% | 2.59% | |
Graham Net Nets |
0.02 | 0.01 | 0.00 | 0.01 | |
Graham Number |
0.00 | 49.70 | 42.44 | 41.19 | |
Earnings Yield |
4.71% | 3.51% | 2.05% | 1.23% | |
Free Cash Flow Yield |
2.56% | 2.52% | 2.64% | 1.75% | |
Revenue per Share |
12.14 | 11.57 | 10.88 | 11.14 | |
Operating CF per Share |
0.00 | 1.28 | 1.63 | 2.61 | |
Capex per Share |
0.00 | (0.54) | (0.40) | (2.12) | |
Free Cash Flow per Share |
0.00 | 0.74 | 1.23 | 0.48 | |
Cash per Share |
8.43 | 7.72 | 6.86 | 10.18 | |
Shareholders Equity per Share |
22.77 | 20.52 | 18.61 | 21.54 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
22.77 | 20.52 | 18.61 | 21.54 | |
Free Cash Flow |
66.40 | 51.10 | 86.00 | 33.90 | |
Working Capital |
1,227.10 | 1,104.90 | 1,022.00 | 1,233.90 | |
Capital Expenditures |
(57.10) | (37.30) | (27.80) | (149.40) | |
Net Current Asset Value |
205.50 | 106.20 | 24.90 | 238.80 | |
EV/EBIT |
16.04 | 21.26 | 29.88 | 42.69 | |
Capex to Sales |
0.00 | 0.05 | 0.04 | 0.19 | |
Price to Operating Income |
15.40 | 20.46 | 28.96 | 42.20 | |
| Other line items | |||||
Average Receivables |
575.60 | 516.60 | 473.50 | 441.20 | |
Average Payables |
105.20 | 109.70 | 103.70 | 47.40 | |
Average Inventory |
499.20 | 465.85 | 451.65 | 441.50 | |
Average Assets |
3,222.20 | 3,317.15 | 3,252.25 | 3,139.05 | |
Average Common Equity |
1,481.70 | 1,442.60 | 1,316.65 | 1,363.45 |
Columns are period end dates · fundamentals updated 5 Nov 2026